00460 SIHUAN PHARM

Watchlist

0.670
+0.010+1.52%

Not Open Nov 25 16:08 CST

6.24BMarket Cap-167500P/E (TTM)

About SIHUAN PHARM Company

Sihuan Pharmaceutical Holding Group Co., Ltd. (“Sihuan Pharmaceutical” or the “Company”, together with its subsidiaries is the “Group”) (stock code: 00460.HK) was founded in 2001 and listed on the main board of the Hong Kong Stock Exchange Limited in 2010. It is an international medical, aesthetic and biopharmaceutical enterprise with an independent and leading independent production, research and development (“R&D”) technology platform led by innovation and a mature and excellent sales system. Sihuan Pharmaceutical focuses on high-growth treatment fields such as medical aesthetics, oncology, metabolism, diabetes, cardiovascular, modern traditional Chinese medicine, and industrial marijuana, and has always adhered to the overall strategic goal of “adhering to the full speed promotion of Sihuan Medical Aesthetics and Biopharmaceuticals two-wheel drive strategy” to build a leading medical, aesthetic and biopharmaceutical enterprise in China.

Company Profile

Symbol00460

Company NameSIHUAN PHARM

ISINBMG8162K1137

Listing DateOct 28, 2010

Issue Price4.60

Shares Offered1.25B share(s)

FoundedApr 26, 2006

Registered AddressBermuda

Chairmanfengsheng che

Secretaryyanlinglijianwei chen

Audit InstitutionErnst & Young

Company CategoryOverseas registration of Mainland Individuals control

Registered OfficeClarendon House 2 Church Street Hamilton HM 11 Bermuda

Head Office and Principal Place of BusinessRoom 4905, Convention Plaza Office Tower, 1 Harbour Road, Wanchai, Hong Kong

Fiscal Year Ends12-31

Employees2648

MarketHong Kong motherboard

Phone(010)57693700;(852)36283911

Fax(010)85867669-100

Emailinfo@jsdmss.com

Websitehttp://www.sihuanpharm.com

Business Sihuan Pharmaceutical Holding Group Co., Ltd. is an investment holding company mainly engaged in R&D, manufacturing and sales of pharmaceutical products and medical and aesthetic products. The company operates its business through three divisions. The Medical and Aesthetic Products segment includes fillers, contouring, support, supplements, optoelectronic equipment, body sculpting, skin care, and others, as well as providing comprehensive solutions for light medicine and beauty. The Innovative Drugs and Other Drugs Division develops and commercializes innovative drugs in diseases such as diabetes, breast cancer, digestion, tumors, and non-alcoholic steatohepatitis. The Generic Drugs Division is engaged in the production and sale of generic drugs, including Clarion. The company operates in domestic and foreign markets.

Company Executives

Name
Position
Salary

fengsheng che
Presidencies, Executive Director, Remuneration Committee Members
--

jionglong zhang
Executive Director
--

weicheng guo
Vice-chairman, CEO, Executive Director, Nomination Committee Members, Member of the Risk Management Committee
--

guili mou
Executive Director, Deputy Chief Executive, Chief Financial Officer, Risk Committee Member Co-Chairman
--

yanling chen
Executive Director, Joint Company Secretary, Risk Committee Co-Chairman, Authorized Representative
--

huaguang ceng
Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members, Member of the Risk Management Committee, Remuneration Committee Members
--

xun zhu
Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members, Nomination Committee Members
--

guan wang
Independent Non-Executive Director, Chairman of the Nomination Committee, Audit Committee Members, Remuneration Committee Members
202.00K

jianwei li
Joint Company Secretary, Authorized Representative
--

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data